Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis – efficacy findings up to week 12

Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis – efficacy findings up to week 12

Background It is challenging to select the most appropriate biologic treatment for patients with moderate-to-severe plaque psoriasis. Objective To compare speed of onset and level of skin improvement between the interleukin (IL)-17A antagonist ixekizumab and the IL-23 p19 inhibitors guselkumab, tild...

Full description

Bibliographic Details
Main Authors: Alice B. Gottlieb, Daniel Saure, Stefan Wilhelm, Martin Dossenbach, Christopher Schuster, Saxon D. Smith, Yuval Ramot, Diamant Thaçi
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Journal of Dermatological Treatment
Subjects:
ixekizumab
indirect comparison
psoriasis
interleukin-23 inhibitors
Online Access:http://dx.doi.org/10.1080/09546634.2020.1747592

Internet

http://dx.doi.org/10.1080/09546634.2020.1747592

Similar Items